Browne Gina, Steiner Meir, Roberts Jacqueline, Gafni Amiram, Byrne Carolyn, Dunn Edward, Bell Barbara, Mills Michael, Chalklin Lori, Wallik David, Kraemer James
System-Linked Research Unit on Health and Social Service Utilization, McMaster University, Faculty of Health Sciences, 1200 Main Street West, HSC-3N46, Hamilton, Ontario, Canada L8N 3Z5.
J Affect Disord. 2002 Apr;68(2-3):317-30. doi: 10.1016/s0165-0327(01)00343-3.
There is little information on the long-term effects and costs of a combination of Sertraline and interpersonal psychotherapy (IPT) for the treatment of dysthymia in primary care.
In a single-blind, randomized clinical trial, 707 adults (18-74 years of age inclusive) with DSM-IV dysthymic disorder, with or without past and/or current major depression, as an acute or chronic episode, in a community-based primary care practice in Ontario, Canada, were randomized to treatment with either Sertraline alone (50-200 mg), or IPT alone (10 sessions), or Sertraline plus IPT combined. In the acute treatment phase (first 6 months) all groups received full active treatment. This was followed by an additional 18-month naturalistic follow-up phase. Subjects were assessed for effectiveness of treatment in reducing depressive symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) at 6 months and twice again during the 18-month follow-up by blind independent observers. Treatment costs and subjects' use of other health and social services were also investigated.
At 6 months, 586 subjects completed the MADRS questionnaire. There was a significant difference (P=0.025) in mean MADRS scores: 14.3 (Group I); 14.9 (Group II); 16.8 (Group III), using analysis of covariance. Response (40% improvement) rates were 60.2% for Sertraline alone, 46.6% for IPT alone, and 57.5% for Sertraline augmented by IPT (P=0.02). At 2 years, 525 subjects were retained for follow-up. There was no statistically significant difference between Sertraline alone and Sertraline plus IPT in symptom reduction. However, both were more effective than IPT alone in reducing depressive symptoms (P=0.03). There was a statistically significant difference between groups in costs for use of health and social services. The IPT treatment groups had the lower costs for use of health and social services.
Sertraline or Sertraline plus IPT was more effective than IPT alone after 6 months. Over the long term (2 years), all three treatments provide reasonably effective treatment for reducing symptoms of dysthymia, but Sertraline or combining Sertraline with IPT is more effective than IPT alone. Of these two more effective treatments, subjects in the Sertraline plus IPT group had less health and social service costs by $480 per person over 2 years. These findings underscore the effects of combining pharmacotherapy and psychotherapy and the economic value of this more comprehensive treatment of dysthymia in primary care.
关于舍曲林与人际心理治疗(IPT)联合治疗基层医疗中恶劣心境障碍的长期效果及成本的信息较少。
在一项单盲随机临床试验中,加拿大安大略省一家社区基层医疗诊所的707名年龄在18至74岁(含)之间、患有DSM-IV恶劣心境障碍(无论有无既往和/或当前的重度抑郁,为急性或慢性发作)的成年人,被随机分为单独使用舍曲林(50 - 200毫克)治疗组、单独使用IPT(10次治疗)治疗组或舍曲林加IPT联合治疗组。在急性治疗阶段(前6个月),所有组均接受充分积极的治疗。随后是为期18个月的自然随访阶段。由盲法独立观察者在6个月时以及在18个月随访期间再次两次使用蒙哥马利-阿斯伯格抑郁评定量表(MADRS)评估受试者治疗减轻抑郁症状的有效性。还调查了治疗成本以及受试者对其他健康和社会服务的使用情况。
6个月时,586名受试者完成了MADRS问卷。使用协方差分析,平均MADRS得分存在显著差异(P = 0.025):单独使用舍曲林组为14.3;单独使用IPT组为14.9;舍曲林加IPT联合治疗组为16.8。单独使用舍曲林的缓解率(改善40%)为60.2%,单独使用IPT为46.6%,舍曲林加IPT为57.5%(P = 0.02)。2年时,525名受试者被保留进行随访。单独使用舍曲林与舍曲林加IPT在症状减轻方面无统计学显著差异。然而,两者在减轻抑郁症状方面均比单独使用IPT更有效(P = 0.03)。在健康和社会服务使用成本方面,各组之间存在统计学显著差异。IPT治疗组在健康和社会服务使用方面成本较低。
6个月后,舍曲林或舍曲林加IPT比单独使用IPT更有效。从长期(2年)来看,所有三种治疗方法在减轻恶劣心境障碍症状方面均提供了合理有效的治疗,但舍曲林或舍曲林与IPT联合使用比单独使用IPT更有效。在这两种更有效的治疗方法中,舍曲林加IPT组的受试者在2年期间每人的健康和社会服务成本比单独使用舍曲林组少480美元。这些发现强调了药物治疗与心理治疗联合的效果以及这种更全面治疗基层医疗中恶劣心境障碍的经济价值。